Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022
Pathogens · 31.08.2024 · 13 (9) · 750
DOI: 10.3390/pathogens13090750 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pathogens, online erschienen am 31.08.2024. Verfasst von Tal Brosh-Nissimov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba 84101, Israel. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a significant cause of illness in adults, especially older adults and those with underlying conditions. This study aimed to assess the incidence of RSV hospitalizations in adults and identify risk factors for hospitalization and poor outcomes.
Methods
A retrospective cohort study was conducted using data from two hospitals in southern Israel from 2016–2022. We calculated incidence rates of RSV and influenza hospitalizations. Risk factors for hospitalization were analyzed using Poisson regression. We evaluated poor outcomes (death, ICU admission, or mechanical ventilation) among RSV-hospitalized patients.
Results
The median annual incidence of RSV hospitalization was 28.2/100,000 population, increasing with age to 199/100,000 in those ≥75 years. Significant risk factors for RSV hospitalization included pulmonary diseases (RR 4.2, 95% CI 3.4–5.2), cardiovascular diseases (RR 3.3, 95% CI 2.6–4.2), and chronic renal failure (RR 2.9, 95% CI 2.3–3.7). Among hospitalized RSV patients, 13.9% had poor outcomes. Renal failure (RR 1.81, 95% CI 1.23–2.66), neutropenia (RR 2.53, 95% CI 1.19–5.35), neutrophilia (RR 1.66, 95% CI 1.81–2.34), and lymphopenia (RR 2.03, 95% CI 1.37–3.0) were associated with poor outcomes.
Conclusions
RSV causes a substantial burden of hospitalizations in adults, particularly among older adults and those with comorbidities. Identifying high-risk groups can help target prevention and treatment strategies, including vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba 84101, Israel.
- Infectious Diseases Unit, Samson Assuta Ashdod University Hospital, Ashdod 7747629, Israel.
- Clinical Research Center, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheba 84101, Israel.
- Infectious Disease Institute, Soroka University Medical Center, Beer Sheba 84101, Israel.
ORCID-Profile: Amos Cahan, Nitzan Burrack, Lior Nesher
Zitieren
APA
Brosh-Nissimov, T., Ostrovsky, D., Cahan, A., Maaravi, N., Leshin-Carmel, D., Burrack, N., Gorfinkel, R., & Nesher, L. (2024). Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022. Pathogens, 13(9), 750. https://doi.org/10.3390/pathogens13090750
Vancouver
Brosh-Nissimov T, Ostrovsky D, Cahan A, Maaravi N, Leshin-Carmel D, Burrack N, et al. Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022. Pathogens. 2024;13(9):750. doi:10.3390/pathogens13090750
BibTeX
@article{BroshNissimov2024,
author = {Brosh-Nissimov, Tal and Ostrovsky, Daniel and Cahan, Amos and Maaravi, Nir and Leshin-Carmel, Daniel and Burrack, Nitzan and Gorfinkel, Rotem and Nesher, Lior},
title = {Adult Respiratory Syncytial Virus Infection: Defining Incidence, Risk Factors for Hospitalization, and Poor Outcomes, a Regional Cohort Study, 2016–2022},
journal = {Pathogens},
year = {2024},
volume = {13},
number = {9},
pages = {750},
doi = {10.3390/pathogens13090750}
}
EUVIMED